CRISPR

CRISPR1-myl4

ID

ZDB-CRISPR-200708-3

Name

CRISPR1-myl4

Previous Names

None

Target

myl4 (1)

Sequence

5' - AGATCACTTATGCCCAGTGTGGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genome Build: GRCz11Chromosome: 3

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
bw24	myl4

Expression

Gene expression in Wild Types + CRISPR1-myl4

No data available

Phenotype

Phenotype resulting from CRISPR1-myl4

No data available

Phenotype of all Fish created by or utilizing CRISPR1-myl4

Phenotype	Fish	Conditions	Figures
heart myh6 expression increased amount, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 2, Fig. 4 from Ghazizadeh et al., 2019
heart action potential normal duration, ameliorated	myl4^bw24/bw24; bw6Tg	chemical treatment by environment: CARBENOXOLONE	Fig. 5 from Ghazizadeh et al., 2019
heart aldh1a2 expression increased amount, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 2 from Ghazizadeh et al., 2019
heart calcium atom increased amount, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 5 from Ghazizadeh et al., 2019
heart calcium atom normal amount, ameliorated	myl4^bw24/bw24; bw6Tg	chemical treatment by environment: gap junctional intercellular communication inhibitor	Fig. 5 from Ghazizadeh et al., 2019
heart contraction decreased frequency, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 3 from Ghazizadeh et al., 2019
heart action potential increased duration, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 5 from Ghazizadeh et al., 2019
heart Luciferase expression decreased amount, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 3 from Ghazizadeh et al., 2019
heart action potential normal duration, ameliorated	myl4^bw24/bw24; bw6Tg	chemical treatment by environment: gap junctional intercellular communication inhibitor	Fig. 5 from Ghazizadeh et al., 2019
blood circulation decreased rate, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 3 from Ghazizadeh et al., 2019
heart increased contractility, abnormal	myl4^bw24/bw24; bw6Tg	standard conditions	Fig. 3 from Ghazizadeh et al., 2019
heart calcium atom normal amount, ameliorated	myl4^bw24/bw24; bw6Tg	chemical treatment by environment: CARBENOXOLONE	Fig. 5 from Ghazizadeh et al., 2019

Citations

Include unpublished citations

Ghazizadeh, Z., Kiviniemi, T.O., Olafsson, S., Plotnick, D., Beerens, M., Zhang, K., Gillon, L., Steinbaugh, M., Barrera, V., Ho Sui, S., Werdich, A.A., Kapur, S., Eranti, A., Gunn, J., Jalkanen, J., Airaksinen, J., Kleber, A.G., Hollmén, M., MacRae, C.A. (2019) A Metastable Atrial State Underlies The Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation. Circulation. 141(4):301-312

1 - 1 of 1

Show